-transparent.png){kind=logo}
Aminoglutethimide without glucocorticoid has been shown to be a clinically effective treatment for postmenopausal breast cancer in low dosage (250 mg day-1). The mechanism of action of this approach is thought to be the inhibition of peripheral aromatase, the enzyme which converts androstenedione to oestrone. The activity of this enzyme was measured in vivo by injection with 3H-androstenedione and 14C-oestrone and found to be 0.20% +/- 0.05 in 5 patients on low dose AG therapy. In comparison with previously published data this demonstrates a 92% inhibition of peripheral aromatase activity confirming aromatase inhibition as a viable aim in the endocrine treatment of breast cancer.
M Dowsett, and
S J Santner, and
R J Santen, and
S L Jeffcoate, and
I E Smith
January 1978,
Surgical forum,
M Dowsett, and
S J Santner, and
R J Santen, and
S L Jeffcoate, and
I E Smith
May 1983,
British journal of cancer,
M Dowsett, and
S J Santner, and
R J Santen, and
S L Jeffcoate, and
I E Smith
February 1989,
European journal of cancer & clinical oncology,
M Dowsett, and
S J Santner, and
R J Santen, and
S L Jeffcoate, and
I E Smith
January 1987,
Cancer immunology, immunotherapy : CII,
M Dowsett, and
S J Santner, and
R J Santen, and
S L Jeffcoate, and
I E Smith
January 1991,
European journal of cancer (Oxford, England : 1990),
M Dowsett, and
S J Santner, and
R J Santen, and
S L Jeffcoate, and
I E Smith
September 1984,
Lancet (London, England),
M Dowsett, and
S J Santner, and
R J Santen, and
S L Jeffcoate, and
I E Smith
June 1994,
Metabolism: clinical and experimental,
M Dowsett, and
S J Santner, and
R J Santen, and
S L Jeffcoate, and
I E Smith
January 1985,
European journal of cancer & clinical oncology,
M Dowsett, and
S J Santner, and
R J Santen, and
S L Jeffcoate, and
I E Smith
October 1985,
British journal of cancer,
M Dowsett, and
S J Santner, and
R J Santen, and
S L Jeffcoate, and
I E Smith
September 1998,
Clinical cancer research : an official journal of the American Association for Cancer Research,
